- Propanc is developing PPC-001, a combination of trypsinogen and chymotrypsinogen.
Propanc reported encouraging stability and assay development results for its lead candidate PPC-001, supporting preparations for a Phase 1b study in up to 50 advanced cancer patients. The news is a positive but early-stage step for the small-cap biotech.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.